GSK (LON:GSK) Receives Buy Rating from Shore Capital Group

Shore Capital Group restated their buy rating on shares of GSK (LON:GSK) in a research report report published on Wednesday morning, MarketBeat reports.

Several other research firms also recently commented on GSK. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. UBS Group reiterated a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. Finally, Citigroup increased their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,917.86.

GSK Stock Down 0.4%

Shares of GSK stock opened at GBX 2,046 on Wednesday. The firm has a market cap of £82.07 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.24 and a beta of 0.32. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,282. The stock has a 50-day simple moving average of GBX 2,031.72 and a 200-day simple moving average of GBX 1,825.76.

GSK (LON:GSK) last released its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. On average, equities research analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Luke Miels sold 15,579 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Also, insider Anne Beal bought 196 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. In the last ninety days, insiders purchased 11,447 shares of company stock worth $24,273,097. 0.26% of the stock is owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.